Literature DB >> 11161568

Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization.

D Shin1, G Garcia-Cardena, S Hayashi, S Gerety, T Asahara, G Stavrakis, J Isner, J Folkman, M A Gimbrone, D J Anderson.   

Abstract

The transmembrane ligand ephrinB2 and its receptor tyrosine kinase EphB4 are molecular markers of embryonic arterial and venous endothelial cells, respectively, and are essential for angiogenesis. Here we show that expression of ephrinB2 persists in adult arteries where it extends into some of the smallest diameter microvessels, challenging the classical view that capillaries have neither arterial nor venous identity. EphrinB2 also identifies arterial microvessels in several settings of adult neovascularization, including tumor angiogenesis, contravening the dogma that tumor vessels arise exclusively from postcapillary venules. Unexpectedly, expression of ephrinB2 also defines a stable genetic difference between arterial and venous vascular smooth muscle cells. These observations argue for revisions of classical concepts of capillary identity and the topography of neovascularization. They also imply that ephrinB2 may be functionally important in neovascularization and in arterial smooth muscle, as well as in embryonic angiogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161568     DOI: 10.1006/dbio.2000.9957

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  91 in total

Review 1.  Molecular control of arterial-venous blood vessel identity.

Authors:  Ralf H Adams
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

2.  Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells.

Authors:  Ken-Ichiro Nagashima; Akira Endo; Hisakazu Ogita; Akiko Kawana; Akiko Yamagishi; Akira Kitabatake; Michiyuki Matsuda; Naoki Mochizuki
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

Review 3.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

Review 4.  Eph and ephrin signaling in mammary gland morphogenesis and cancer.

Authors:  Anne-Catherine Andres; Andrew Ziemiecki
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

5.  Notch4 normalization reduces blood vessel size in arteriovenous malformations.

Authors:  Patrick A Murphy; Tyson N Kim; Gloria Lu; Andrew W Bollen; Chris B Schaffer; Rong A Wang
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

6.  Possible role of Efnb1 protein, a ligand of Eph receptor tyrosine kinases, in modulating blood pressure.

Authors:  Zenghui Wu; Hongyu Luo; Eric Thorin; Johanne Tremblay; Junzheng Peng; Julie L Lavoie; Yujia Wang; Shijie Qi; Tao Wu; Jiangping Wu
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

Review 7.  Axon guidance molecules in vascular patterning.

Authors:  Ralf H Adams; Anne Eichmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03-31       Impact factor: 10.005

Review 8.  Eph/ephrin molecules--a hub for signaling and endocytosis.

Authors:  Mara E Pitulescu; Ralf H Adams
Journal:  Genes Dev       Date:  2010-11-15       Impact factor: 11.361

Review 9.  EphBs and ephrin-Bs: Trans-synaptic organizers of synapse development and function.

Authors:  Nathan T Henderson; Matthew B Dalva
Journal:  Mol Cell Neurosci       Date:  2018-07-19       Impact factor: 4.314

10.  Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells.

Authors:  Michael H Davies; David O Zamora; Justine R Smith; Michael R Powers
Journal:  Microvasc Res       Date:  2009-02-13       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.